BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26345518)

  • 1. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
    Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
    Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
    Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
    Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
    Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
    Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia.
    Semsei AF; Erdelyi DJ; Ungvari I; Csagoly E; Hegyi MZ; Kiszel PS; Lautner-Csorba O; Szabolcs J; Masat P; Fekete G; Falus A; Szalai C; Kovacs GT
    Cell Biol Int; 2012 Jan; 36(1):79-86. PubMed ID: 21929509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
    Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
    J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
    Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
    J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
    Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
    J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
    Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
    J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
    Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
    N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
    Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
    N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
    Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
    J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL.
    Krajinovic M; Robaey P; Chiasson S; Lemieux-Blanchard E; Rouillard M; Primeau M; Bournissen FG; Moghrabi A
    Pharmacogenomics; 2005 Apr; 6(3):293-302. PubMed ID: 16013960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors.
    Caru M; Corbin D; Périé D; Lemay V; Delfrate J; Drouin S; Bertout L; Krajinovic M; Laverdière C; Andelfinger G; Sinnett D; Curnier D
    Clin Res Cardiol; 2019 Sep; 108(9):1000-1008. PubMed ID: 30778669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
    Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
    Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography.
    Lenk MK; Zeybek C; Okutan V; Ozcan O; Gökçay E
    Turk J Pediatr; 1998; 40(3):373-83. PubMed ID: 9763901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with ALL.
    Zaruma-Torres F; Lares-Asseff I; Reyes-Espinoza A; Loera-Castañeda V; Chairez-Hernández I; Sosa-Macías M; Galaviz-Hernández C; Almanza-Reyes H
    Drug Metab Pers Ther; 2015 Sep; 30(3):195-201. PubMed ID: 26353179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.